TrialNature medicine2023

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.

Spyros Chalkias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.